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The fields of pharmacogenomics and pharmacoepidemiology are 
interrelated in that the goal of both is to understand why individuals 
respond differently to drug therapy, in terms of both adverse effects 
and treatment efficacy. Pharmacogenomics focuses on under-
standing how genetic variants that encode for drug-metabolizing 
enzymes, drug transporters, drug targets, and proteins involved in 
disease biology influence individual differences in terms of treatment 
efficacy, effectiveness, and adverse effects. Pharmacoepidemiology 
uses a variety of study designs to identify patterns and determinants 
of the use of drug therapy and its effects in clinical and population 
settings. The study of genomic factors can be readily integrated into 
pharmacoepidemiologic studies along with nongenetic factors, 
leading to a natural convergence of the two fields.
Five key trends are creating new opportunities, challenges, and 
questions in cancer research. These include 1) expanded develop-
ment and approval of new cancer therapies allowing more 
therapeutic choices, 2) rapid expansion of knowledge and high-
throughput tools to evaluate genomic variation, 3) increasing 
numbers of cancer survivors who may experience late effects of 
treatment, 4) widespread use of prescription pharmaceutical agents 
in the United States population, and 5) increasing numbers of 
public–private partnerships and research consortia. The tools and 
methods of pharmacogenomics and pharmacoepidemiology are 
well suited to study and take advantage of these trends and to 
conduct studies that can inform personalized cancer prevention 
and treatment.
Recent advances in genetic technology, combined with new 
discoveries in pharmacogenomics, have shed light on the substan-
tial role of genomic factors to predict drug response and the clin-
ical potential of genomic testing. Several pharmacogenomic 
markers have been or are currently being evaluated to determine 
their clinical value (Table 1). Examples of these markers include 
cytochrome P450 2D6 (CYP2D6) genotypes in tamoxifen treatment 
for breast cancer (1), UDP-glucuronosyltransferase 1A1 (UGT1A1) 
genotypes in irinotecan treatment for colorectal cancer (2), and 
epidermal growth factor receptor (EGFR) mutations in non–small 
cell lung cancer treatment (3,4). These markers may be able to 
identify subgroups of patients who will optimally benefit from a 
particular cancer therapy, other patients who might derive little or 
no benefit, and/or individuals who are at elevated risk for serious 
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Recent advances in genomic research have demonstrated a substantial role for genomic factors in predicting response to cancer 
therapies. Researchers in the fields of cancer pharmacogenomics and pharmacoepidemiology seek to understand why individ-
uals respond differently to drug therapy, in terms of both adverse effects and treatment efficacy. To identify research priorities 
as well  as  the  resources  and  infrastructure  needed  to  advance  these  fields,  the National  Cancer  Institute  (NCI)  sponsored  a 
workshop  titled  “Cancer  Pharmacogenomics:  Setting  a  Research  Agenda  to  Accelerate  Translation”  on  July  21,  2009,  in 
Bethesda, MD.  In  this  commentary, we  summarize and discuss  five  science-based  recommendations and  four  infrastructure-
based  recommendations  that  were  identified  as  a  result  of  discussions  held  during  this  workshop.  Key  recommendations 
include 1) supporting the routine collection of germline and tumor biospecimens  in NCI-sponsored clinical  trials and  in some 
observational and population-based studies; 2)  incorporating pharmacogenomic markers  into clinical  trials; 3) addressing  the 
ethical,  legal,  social,  and  biospecimen-  and  data-sharing  implications  of  pharmacogenomic  and  pharmacoepidemiologic  re-
search; and 4) establishing partnerships across NCI, with other federal agencies, and with industry. Together, these recommen-
dations will facilitate the discovery and validation of clinical, sociodemographic, lifestyle, and genomic markers related to cancer 
treatment response and adverse events, and they will improve both the speed and efficiency by which new pharmacogenomic 
and pharmacoepidemiologic information is translated into clinical practice.
J Natl Cancer Inst 2010;102:1698–1705
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adverse events. However, the clinical utility for the most promising 
pharmacogenomic markers is still being investigated.
A few genetic and genomic tests have recently been integrated 
into standard clinical practice and/or incorporated into the Food 
and Drug Administration (FDA) label. However, there appears to 
be substantial variation in the rate of clinical adoption and accep-
tance of such testing. At one extreme, testing for KRAS mutations 
to determine whether to use cetuximab and panitumumab in treat-
ing metastatic colorectal cancer was adopted quickly (5). By con-
trast, testing of thiopurine methyltransferase (TPMT) genotypes to 
determine optimal treatment for acute lymphocytic leukemia (6) 
and of EGFR mutations and/or expression to determine non–small 
cell lung cancer treatment (4) has been variable in clinical practice. 
So, the discovery of substantial genomic influence over the effec-
tiveness or safety of a cancer drug does not always translate imme-
diately into clinical practice. There may be numerous reasons 
for this variability: Oncologists may not be convinced that the 
genomic test is of clinical value, physicians may not know about 
the tests, drug labels may not describe the usefulness of genetic 
information, or insurance coverage may not be available for the 
genetic test (Table 1). For example, in the case of TPMT testing, 
some physicians may not be convinced of its clinical utility and/or 
cost-effectiveness and they may believe that how they currently 
manage chemotherapy-induced myelosuppression is an adequate 
way to screen for potential toxicities. Also, many physicians may 
have never treated the rare (one in 400) homozygous patient who 
would experience life-threatening toxicity without TPMT testing.
Discoveries from cancer pharmacogenomics and pharmaco-
epidemiology research can help to optimize the benefit to risk 
ratio of treatment strategies in general clinical practice. 
Translation of these discoveries may more efficiently target ther-
apies to patients who will benefit and avoid or anticipate poten-
tially serious adverse events among high-risk patients and thus 
may reduce cancer morbidity and mortality and reduce the cost of 
cancer care. Equally important, these discoveries provide novel 
insights into the underlying biology of drug response phenotypes. 
Full realization of the potential of pharmacogenomics research 
will require the integration of basic discoveries in drug develop-
ment and pharmacogenomic variability, of genomic and outcome 
data from phase I–III randomized clinical trials, and of data on the 
effects of drugs and their interactions with genomic variants in 
large populations. Here, we report on results from the National 
Cancer Institute (NCI)–sponsored workshop titled “Cancer 
Pharmacogenomics: Setting a Research Agenda to Accelerate 
Translation” which took place on July 21, 2009 and the group’s 
recommendations to address priorities, resources, and infrastruc-
ture needs to advance the fields of cancer pharmacoepidemiology 
and pharmacogenomic research (7).
Methods
To address the interdisciplinary and translational nature of this 
field, and the need for input across various disciplines, the Trans-
NCI Pharmacogenomics and Pharmacoepidemiology Working 
Group (PPWG) was chartered by NCI in January 2008 (8). The 
PPWG is responsible for planning, developing, directing, coordi-
nating, and evaluating a program of research in pharmacogenom-
ics and pharmacoepidemiology research across NCI. To begin this 
task, three subcommittees of the PPWG were created to address 
issues specific to basic biomedical research, clinical research, and 
population science research. Each subcommittee identified pri-
ority areas and research goals important to their specific area of 
research, analyzed the portfolio of NCI-sponsored pharmacoge-
nomics and pharmacoepidemiology studies of common pharma-
ceuticals and cancer therapies, and developed recommendations 
to advance a pharmacogenomics and pharmacoepidemiology 
Table 1. Pharmacogenomic markers in cancer treatment*
Biomarkers Drug Cancer site Effect
Information included  
in the FDA drug label
Routinely used in 
United States practices
Germline variants
  CYP2D6 Tamoxifen Breast Response No No
  UGT1A1 Irinotecan Colorectal Safety Yes No
  CYP3A4 Dasatinib ALL Response No No
  TPMT 6-MP, 6-TG ALL and AML Safety Yes Variable
  DPYD 5-FU Breast/colorectal Safety No No
Somatic alterations
 ERBB2 Trastuzumab Breast Response Yes Yes
 KRAS Cetuximab Colorectal Response Yes Yes
 KRAS Panitumumab Colorectal Response Yes Yes
 BCR-ABL1 Imatinib CML Response Yes Variable
 KIT Imatinib CML/ALL Response Yes Variable
Protein expression
 EGFR Erlotinib Lung Response No No
 EGFR Gefitinib Lung Response No No
 Oncotype Dx Tx Regimen Breast Response No Yes
 Mammoprint Tx Regimen Breast Response Yes† No
 EGFR Cetuximab Colorectal Response Yes No
* 5-FU = 5-fluorouracil; 6-MP = 6-mercaptopurine; 6-TG = 6-thioguanine; ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; CML = chronic 
myelogenous leukemia; EGFR = epidermal growth factor receptor; FDA = Food and Drug Administration; Tx = treatment.
† Device approval.
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research agenda at NCI. The subcommittee recommendations 
were then brought to the full PPWG to be combined in a final 
draft of summary recommendations.
To further refine the recommendations, input was sought from 
members of the broader cancer research community. In July 2009, 
NCI brought together these external scientists with representa-
tives of the PPWG, the National Institutes of Health, and other 
key federal agencies (eg, the United States FDA, the Agency for 
Healthcare Research and Quality, the Centers for Disease Control 
and Prevention [CDC], and the Department of Defense) to partic-
ipate in an NCI-sponsored workshop at which invitees discussed 
the draft recommendations, priorities for cancer pharmacogenom-
ics and pharmacoepidemiology research initiatives, and the needs 
of the fields in general. The resulting nine recommendations are 
presented in this commentary.
Overview of Recommendations: Future 
Research Directions
The recommendations reflect the input of NCI and extramural 
clinical and research investigators from a wide variety of disci-
plines, including medical oncology, genomics, clinical and basic 
pharmacology, epidemiology, statistics, health services, pathology, 
molecular biology, and bioinformatics, among others. The goal 
of these recommendations is to improve both the speed and 
efficiency of discovery and the translation of this rapidly evolving 
new knowledge into clinical practice. These recommendations 
will serve as the roadmap for the programs, resources, and 
infrastructure needed to maintain a pipeline of such discoveries. 
Here we summarize the priorities relevant to each of the nine rec-
ommendations, which have been divided into five scientific-based 
recommendations and four infrastructure-based recommendations 
(Table 2).
Knowledge Gaps in Pharmacogenomics and 
Pharmacoepidemiology
Recognizing the need to identify gaps in knowledge and to priori-
tize research, recommendation 1 calls for the development and 
ongoing support of an expert panel tasked on an ongoing basis to 
synthesize evidence, identify knowledge gaps, and develop prior-
ities and specific research questions with the goal of speeding 
translation of pharmacogenomics and pharmacoepidemiology re-
search findings into clinical practice. This group would synthesize 
and process pharmacogenomic and pharmacoepidemiologic evi-
dence relevant to cancer from trials and observational studies and 
would provide guidance as to the additional study data that would 
be needed to translate new evidence into clinical practice. Several 
ongoing initiatives could be leveraged for this group, of which 
three are CDC initiatives––the Evaluation of Genomic Applications 
in Practice and Prevention initiative (9), the Human Genome 
Epidemiology Network (10), and the new Genomic Applications 
in Practice and Prevention Network (11)––and one from the 
National Institutes of Health’s Pharmacogenetics Research 
Network, the Pharmacogenetics and Pharmacogenomics 
Knowledge Base (PharmGKB) (12). Ideally comprised of members 
from the public as well as private entities, the group would consist 
Table 2. Key recommendations
1. Develop and support a knowledge synthesis study group/board to identify gaps and prioritize cancer pharmacoepidemiology and  
pharmacogenomic research.
2. Develop and support opportunities to identify clinical, sociodemographic, lifestyle, and genomic markers related to treatment response and/or 
adverse events in NCI-sponsored clinical trials.
 Support pharmacoepidemiology and pharmacogenomic studies using previously collected clinical data and biospecimens from existing and 
ongoing clinical trials.
 Develop and support opportunities to routinely collect and store DNA specimens in new and existing NCI-sponsored clinical trials for future 
pharmacogenomic analyses.
 Develop and support the incorporation of pharmacogenomic markers and/or epidemiological information into the design of clinical trials.
3. Support observational studies that identify clinical, sociodemographic, lifestyle, and genomic factors of treatment response and adverse events.
 Use predictive clinical, sociodemographic, lifestyle, and genomic factors associated with treatment response and adverse events discovered 
in clinical trial analyses to develop and support opportunities to validate findings in large, heterogeneous, observational studies.
 Develop and support opportunities to identify predictive factors of treatment response and adverse events that cannot be obtained using  
existing clinical trial and correlative study data.
 Support observational studies of cancer patients (eg, patient cohorts) with standardized protocols and comprehensive biospecimen collections 
at multiple time points to identify clinical, sociodemographic, lifestyle, and genomic factors that affect cancer treatment and prevention outcomes.
 Support observational studies of pharmacoepidemiology of cancer prevention and risk.
4. Support basic pharmacology research on the pharmacodynamics, pharmacokinetics, and targets of cancer drugs, and their relationships with 
genetic variations that affect drug response because of differential gene expression, protein production, receptor-binding affinity, and enzyme 
level and activity.
5. Provide support for research on the utility of promising pharmacogenetic applications in general clinical practice.
6. Support health information technology enhancements in existing research networks and data systems to facilitate pharmacoepidemiology 
and pharmacogenomic studies of observational and clinical trial data.
7. Support research on the ethical, legal, social, and data-sharing implications of collecting biospecimens for pharmacogenomics research in 
population-based and clinical trial research settings.
8. Support the development of transdisciplinary training programs in cancer pharmacogenomics and pharmacoepidemiology.
9. Support, facilitate, and coordinate a trans-NCI effort to partner with other relevant groups, including other federal agencies and  
industry to develop initiatives and activities in pharmacogenomic and pharmacoepidemiology cancer research that ensure the  
integration of basic, clinical, and population sciences.
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of scientists, policy makers, and patient advocates. Membership 
should reflect a broad spectrum of expertise, including oncology, 
genomics, clinical and basic pharmacology, epidemiology, and 
clinical medicine.
Pharmacogenomics and Pharmacoepidemiology Within 
Clinical Trials
Recommendation 2 calls for support of the collection, storage, and 
analysis of biospecimens from clinical trials. The workshop partic-
ipants noted that in clinical trials, biospecimens are not routinely 
collected; therefore, the availability of tumor and DNA samples 
varies considerably across studies. Even when such samples have 
been collected and stored, there has been limited use of the exist-
ing clinical and biospecimens data for pharmacogenomic and 
pharmacoepidemiologic research. Workshop participants agreed 
that studies, including genome-wide association studies (GWAS), 
that use previously collected clinical data and biospecimens from 
existing and ongoing clinical trials could provide important data 
that could be rapidly translated into clinical practice and improve 
treatment management. To promote the pursuit of such studies, it 
will be necessary to coordinate access, collection, inventory, and 
pooling of clinical trial data and specimens across trials and across 
sponsors. Mechanisms for long-term follow-up of clinical trial 
patients also need to be developed to examine long-term benefits 
and adverse late effects of various treatments. Last, it is important 
to develop rapid, open, transparent, and equitable processes for the 
review of applications for access to these biospecimens.
As of June 2008, more than 300 000 blood samples that had 
been collected from patients from NCI-sponsored Clinical Trials 
Cooperative Group Program trials (13,14) were stored in tissue 
banks. Even more samples are potentially available through the 
NCI-sponsored Specialized Programs of Research Excellence (15), 
Cancer Centers (16), and individual investigator research projects. 
Pharmaceutical company–sponsored studies are another major 
source of biospecimens if data sharing, material transfer agreements, 
and access for outside investigators can be negotiated. Important 
research findings using retrospective analyses of tumor markers 
from completed clinical trials already have been successfully trans-
lated into clinical practice. For example, numerous clinical trials 
have shown that colorectal cancer therapy with cetuximab or pani-
tumumab is ineffective in tumors with somatic mutations in 
codons 12 and 13 of exon 2 of the KRAS gene. These findings 
prompted the American Society of Clinical Oncology to develop 
guidelines to target the clinical use of these drugs based on these 
genetic markers (17) and the European Medicines Agency and the 
FDA to include these data in the prescribing information for 
cetuximab and panitumumab.
Collaborations have been established between Pharmacogenetic 
Research Network investigators (18), the NCI, the Cooperative 
Groups, and the Rikagaku Kenkyusho Center for Genomic 
Medicine in Japan (19) to use GWAS to find genetic variations of 
germline DNA associated with cancer treatment and prevention 
responses and adverse events. A recent GWAS from the 
Postmenopausal Breast Cancer Adjuvant Trial MA.27 found sev-
eral single-nucleotide polymorphisms associated with musculo-
skeletal adverse events in women who received adjuvant therapy 
with aromatase inhibitors for early breast cancer (20). These novel 
findings may lead to the prevention of musculoskeletal adverse 
events in women who receive these therapies, and they specifically 
illustrate the incredible opportunity to advance discoveries in per-
sonalized cancer medicine by conducting pharmacogenomic 
research using pooled trial data and specimens.
Federal agencies can ensure that collected specimens are avail-
able and are used to answer critical clinical questions most effi-
ciently by 1) establishing mechanisms and common protocols that 
allow specimens to be pooled across studies and shared with out-
side investigators; 2) creating a searchable inventory of specimen 
collections, accompanied by annotated data for each patient, 
to facilitate their use; and 3) developing mechanisms to fund main-
tenance of biospecimen repositories and sustained long-term 
follow-up of trial participants, including cohorts created de novo 
across trials.
Answering future research questions requires a substantial 
amount of planning and coordination today. As much as possible, 
the most versatile DNA specimens should be collected for future 
research use (eg, blood samples may provide more analytic flexi-
bility than saliva samples). Methods for specimen collection, 
storage, and handling should be standardized to provide consis-
tently high-quality samples that can be pooled across studies. 
However, the samples alone are of little value without careful 
annotation of drug exposures, clinical outcomes, and demo-
graphics. Additionally, information concerning dietary, environ-
mental, and other lifestyle factors should be collected to greatly 
add to the validity of studies. Currently, information concerning 
these variables is not consistently collected within clinical trials nor 
coordinated across studies. The development of new statistical 
methodologies is needed to harmonize, manage, and analyze these 
large and complex pooled datasets. The Breast Cancer Intergroup 
of North America has established systems and procedures for 
sharing specimens and has already conducted several collaborative 
pharmacogenomic research investigations. Lessons learned from 
their successes and challenges can help direct efforts for other 
cancer and clinical trial networks (21).
Pharmacogenomics and Pharmacoepidemiology in 
Observational and Population-Based Studies
Recommendation 3 calls for the support of observational studies 
that identify clinical, sociodemographic, lifestyle, clinical, and ge-
nomic factors that influence treatment response and/or adverse 
events. Observational studies can be useful to validate clinical trial 
findings of predictive factors associated with treatment response 
and adverse events and to evaluate treatments in patients who were 
not represented in the clinical trials. Observational studies can be 
particularly important to assess rare adverse events and the impact 
of age, organ-system impairment, lifestyle factors, and other dis-
eases on the effectiveness and safety of newly approved therapies.
In many situations, specimens and/or clinical and epidemiolog-
ical data, such as comorbid conditions and lifestyle factors, may not 
have been collected in adequate numbers within existing clinical 
trials and correlative studies to answer important clinical ques-
tions. In these situations, observational studies can be helpful to 
discover and validate new associations. These studies may include 
analyses of 1) rare or long-term events, including toxicities and 
future outcomes of cancer; 2) effects or outcomes of off-label use; 
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3) drug–drug interactions; and 4) contributions of lifestyle, demo-
graphic factors, and other comorbid conditions. Observational 
studies would help to confirm the importance of genomic varia-
tions identified in cancer therapy trials, particularly when trials are 
underpowered, and also to study the impact of genetic variations 
in response to therapy and/or to study toxicities among diverse 
patient populations and ethnic groups that were not adequately 
represented in clinical trials.
There are several examples of how observational studies have 
been used to identify clinically important associations. One recent 
example involves the association of cytochrome P450 2D6 gene 
(CPY2D6) polymorphisms with outcome among women with 
breast cancer who were treated with tamoxifen. Retrospective 
analyses of clinical trials (22–27) showed that breast cancer patients 
who were classified as poor or intermediate metabolizers based on 
their CYP2D6 genotype had unfavorable outcomes on tamoxifen. 
However, the clinical relevance was uncertain because of small 
sample sizes within studies and inconsistent quality and results 
across several clinical studies. Recently, Schroth et al. (28) pub-
lished the first adequately powered study, an observational study of 
a cohort of 1325 breast cancer patients that showed a statistically 
significant association between CYP2D6 genotypes and clinical 
outcomes. This study validated the previous retrospective clinical 
trials analyses and provides additional evidence for the clinical 
relevance of using CYP2D6 genotypes to inform breast cancer 
treatment. A study by Ross et al. (29) that demonstrated that vari-
ants in the genes for thiopurine methyltransferase (TPMT) and 
catechol-O-methyltransferase (COMT) were strongly associated 
with hearing loss among children receiving cisplatin chemotherapy 
is an excellent example of the use of an observational cohort study 
design to identify the cause of an otherwise idiosyncratic adverse 
event. They analyzed candidate genes in an initial cohort of 54 
children treated in pediatric oncology units, followed by a replica-
tion in a second cohort of 112 children recruited through a na-
tional surveillance network for adverse drug reactions in Canada. 
In an example of a pharmacogenomic observational study that 
examined factors related to survival, Chan et al. (30) analyzed a 
prospective cohort of 1279 men and women with colorectal cancer 
and found that regular aspirin use after the diagnosis of colorectal 
cancer is associated with a lower risk of colorectal cancer-specific 
and overall mortality, especially among individuals with tumors 
that overexpressed cyclooxygenase-2.
A comprehensive and coordinated research approach is 
necessary to translate promising findings such as these into clinical 
practice. The workshop participants recommended developing 
and supporting opportunities for the creation of new observational 
patient cohort studies that include standardized and uniform col-
lection of comprehensive specimen and treatment data. These 
patient cohorts would be essential not only for measuring genomic 
factors and biomarkers within high-standard biospecimens but also 
for assessing health behavior and lifestyle factors during critical 
time periods, such as during and shortly after therapy. In addition, 
it would be beneficial to leverage existing population-based 
research studies and networks to answer questions that cannot be 
addressed through existing resources. Such efforts should include 
establishing sustainable cohorts of cancer patients; obtaining epi-
demiological, clinical, and biological data on study participants 
over a number of years; and/or leveraging existing networks, such 
as the NCI-sponsored Health Maintenance Organization–Cancer 
Research Network (31), health maintenance organizations (32), 
and other private entities with electronic medical records through 
which to obtain information on prescription drug use.
Pharmacogenomics in Basic Science
Recommendation 4 calls for support of basic pharmacological re-
search on the pharmacodynamics and pharmacokinetics of drugs 
used in the prevention and treatment of cancer. There is a need to 
better understand complex pharmacokinetic and pharmacody-
namic pathway mechanisms at early stages of drug development as 
well as after drug approval. This includes the study of the targets 
of cancer drugs, and their relationships with genetic variations that 
affect drug response because of differential gene expression, 
protein production, receptor-binding affinity, and/or enzyme level 
and activity. Functional analyses of the proteins encoded by genes 
identified in GWAS also will be valuable in clinically homoge-
neous case subsets. Such research will help to identify the genomic 
contributions to drug response and adverse events and will provide 
novel insight into mechanisms of drug action and disease 
pathophysiology.
There are a number of recent examples of the impact of phar-
macokinetic and pharmacodynamic analysis on our understanding 
of variation of response to cancer treatment. Pharmacokinetic and 
pharmacodynamic evaluation of the CYP2D6-mediated metabo-
lism of tamoxifen implicated endoxifen as the key active metabo-
lite, leading NCI to begin development of endoxifen as an agent to 
be used alone in treating breast cancer (33). Pharmacokinetic and 
pharmacodynamic studies can also inform our mechanistic under-
standing of adverse events. As mentioned above, a recently pub-
lished GWAS (20) identified three single-nucleotide polymorphisms 
on chromosome 14 associated with musculoskeletal adverse events 
in women receiving aromatase inhibitors. Functional analysis of 
these single-nucleotide polymorphisms indicates that they are 
associated with decreased T-cell leukemia/lymphoma protein 1A 
(TCL1A) expression related to estrogen exposure (20).
Clinical Effectiveness, Utility, and Dissemination of 
Pharmacogenomics and Pharmacoepidemiology 
Knowledge
Recommendation 5 provides support for studies of clinical utility 
that focus on the effectiveness of pharmacogenomic applications in 
general clinical practice and the implications of incorporating these 
tests in representative patient populations and/or general popula-
tions. Translational research that moves pharmacoepidemiology 
and pharmacogenomic discoveries from basic science and clinical 
trials to the bedside has been limited at best. Research is needed to 
help clarify the levels of evidence that are needed for acceptable 
adoption of new pharmacogenomics technology into clinical prac-
tice. Although randomized clinical trials are gold standard for 
determining the efficacy of treatments, prospective and retrospec-
tive observational studies with high-quality phenotyping data 
might be adequate for the adoption of some diagnostic tests and 
certain treatment decisions. In addition to assessing immediate 
clinical endpoints, studies should incorporate longer-term out-
comes, such as survival, patient-reported outcomes, and cost–benefit 
D
ow
nloaded from
 https://academ
ic.oup.com
/jnci/article-abstract/102/22/1698/917510 by guest on 30 April 2020
jnci.oxfordjournals.org    JNCI | Commentary 1703
analyses, as well as key factors influencing patients’ decisions and 
preferences for cancer treatment. To address this need, under pro-
visions for the National Institutes of Health in the American 
Recovery and Reinvestment Act, NCI recently funded seven large 
projects (34) for 2-year efforts that will advance methods for the 
evaluation of the clinical validity and utility of existing and 
emerging genomic personalized medicine applications in cancer 
control and prevention. These initiatives should enhance the clin-
ical and population data infrastructure to support comparative ef-
fectiveness research initiatives in genomic personalized medicine.
Dissemination studies that focus on barriers and facilitators to 
wide-scale adoption of proven pharmacogenomic technologies or 
on the overuse or misuse of technologies that have questionable 
risk to benefit profiles should be supported. In addition, research 
on effective processes, such as clinical decision support tools, 
should be supported to integrate pharmacogenomic technologies 
into clinical practice. Furthermore, the existence of different prac-
tice settings, such as rural clinics, academic institutions, medical 
centers, should be taken into account as part of the strategy for 
enhancing the incorporation of pharmacogenomics information 
into regular clinical practice.
Bioinformatics
Recommendation 6 supports the development of new bioinfor-
matics methodologies and statistical expertise to process large vo-
lumes of data and to harmonize and combine existing samples, 
population information, and data. Linking pharmacogenomic and 
pharmacoepidemiology data, particularly the results of GWAS 
regarding the association of gene variants with adverse events, 
drug response, patient characteristics, and other data, will also be 
important. These activities will need to be coordinated with the 
new Biomedical Informatics Grid Health Consortium (35), NCI’s 
cancer Biomedical Informatics Grid (36), Human Genome 
Epidemiology Network (10), and the PharmGKB (11).
Ethical, Legal, Social, and Data-Sharing Implications
Recommendation 7 recognizes a need to implement specific and 
consistent procedures for data sharing and protection of confiden-
tiality. The long-term follow-up of patients, the analysis of stored 
specimens for new purposes, and the sharing of information across 
investigations that includes sharing across government and private 
sector boundaries, bring new legal, ethical, and social challenges 
that must be addressed. Support is needed at all levels, including 
the development of educational resources to help institutional 
review boards better understand that the risks of collecting phar-
macogenomics marker data on patients differ substantially from 
the risks of collecting data for other types of disease markers. Data-
sharing policies will also be needed (especially for multinational 
collaborations), and appropriately flexible informed consent forms 
will be needed to ensure that patients have the opportunity to give 
or deny consent to use their biospecimens and other data in studies 
that may be conceived years––or potentially, even decades––after 
their original consent.
Training
Combining two rather young fields, pharmacogenomics and 
pharmacoepidemiology, depends on the integration of genetics, 
epidemiology, and pharmaceutical sciences, which may require 
additional training and the development of new skill sets. A suc-
cessful investigator in these fields must be conversant in such 
disparate disciplines as pathology, statistical genetics, and infor-
mation technology. Such expertise takes considerable time to 
develop. Recommendation 8 states that efforts are needed 
to expand transdisciplinary training programs in pharmacoge-
nomics, pharmacoepidemiology, and clinical pharmacology. 
Fellowships and career development training grants at NCI, 
FDA, other federal agencies, and universities are needed to pro-
mote doctoral- and postdoctoral-level training to enable physi-
cians and other researchers to obtain these skills.
Coordination and Partnerships of Public and Private 
Entities
Last, workshop participants recommended that the PPWG con-
tinue its work to support, facilitate, and coordinate trans-NCI ef-
forts to develop initiatives and activities in pharmacoepidemiology 
and pharmacogenomic cancer research that ensure the integration 
of the basic, clinical, and population sciences. To facilitate collab-
oration and avoid overlapping efforts beyond the NCI, it will be 
critical to identify ongoing efforts by other federal agencies, in the 
private sector, throughout the European Union, and globally to 
foster partnerships that may include the FDA, HMOs, pharmacy 
benefit providers, the CDC, the Centers for Medicaid and 
Medicare Services, the Agency for Healthcare Research and 
Quality, the Department of Defense, the Department of Veterans 
Affairs, and professional medical societies.
Summary of Workshop: Research Priorities
The advancement of cancer pharmacogenomics and pharmacoepi-
demiology research has promise to facilitate the discovery and 
translation of research findings that will improve clinical decision 
making and increase cancer survival while reducing the harms as-
sociated with cancer treatment. The trans-NCI PPWG and partic-
ipants of an NCI-sponsored Pharmacogenomics Workshop 
considered how best to foster cancer pharmacogenomic and phar-
macoepidemiology research. Their ideas included ways to rapidly 
translate the results of bench research into medical practice and 
ways to test hypotheses generated from epidemiological and clin-
ical investigations in the laboratory. Together, these complemen-
tary and interacting approaches will help us realize the benefits of 
a personalized approach to cancer treatment and prevention. As 
currently envisioned, a cancer pharmacogenomics and pharmaco-
epidemiology initiative will also encourage collaboration across 
disciplines and partner with other federal agencies with shared 
interests to leverage resources and knowledge. The research spon-
sored by such an initiative will improve our understanding of 
adverse drug events through systematic, rather than anecdotal, risk 
to benefit analyses; increase our ability to understand and monitor 
the effects of commonly used drugs on cancer risk; enable us to 
more efficiently track off-label drug use and its effects; improve 
cancer treatment and cancer prevention trial designs; improve 
postmarketing surveillance (particularly of new antineoplastic 
agents); and potentially reduce the cost of cancer care by matching 
treatments to patients most likely to benefit.
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